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ABSTRAK 
Keselamatan semasa pembiusan berkait rapat dengan kestabilan tekanan darah, pemafasan 
dan kebolehan mempertabankan retlek salur pemafasan. SeJain risiko komplikasi 
pembedahan, pembiusan juga mempunyai risiko dan ini menyebabkan pesakit perlu 
diawasi dengan rapi oleb staf yang berpengalaman di bilik pemulihan selepas pembiusan. 
Dengan adanya ubat pembiusan yang baru seperti desflurane, yang mempunyai tahap 
kelamtan yang rendah didalam darah iaitu 0.42, sepatutnya memberikan kadar kesedaran 
dari pembiusan dengan cepat. Pesakit yang pulih kadar kesedarannya dengan cepat selepas 
pembiusan mungkin tidak perlu diawasi atau memerlukan masa yang singkat berada di 
bilik pemulihan tanpa memberikan risiko kepada pesakit Konsep ini dikenali sebagai ' 
fast-1rack'. 
Satu kajian rawak (single blinded) telah dijalankan di Hospital Universiti Sains Malaysia 
bennula bulan Jun 2004 sehingga Jun 2005. Ia meJibatkan pesaldt seramai 60 orang yang 
menjalani pembedahan ortopedik dalam jangka masa 2 jam. Mereka dibahagikan kepada 2 
kumpulan yang sama rata. 
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Objektif kajian ini adalah untuk menguji kebaikan desflurane sebagai ubat pembiusan, 
serta ia membolehkan pesaldt sedar dengan cepat dan mengalami kurang kesan samping. 
Kesemua pesakit dibius dengan menggunakan ubat fentanyl, propofol dan atracurium. 
Semasa pembedahan, pesaldt diberi sama ada destlurane 6% atau sevotlurane 2% ( yang 
mempunyai nilai I MAC untuk kedua-dua ubat dalam lOOOAI oxsigen) berserta 300/o 
oxsigen dan 70% nitrous oxida. Untuk pelumpuhan pesakit, infusi atracurimn diberikan 
dan fentanyl sebagai ubat penahan sakit. Tekanan darah dan denyutan nadi dicatat sebelum 
pembiusan, sebelum intubasi, selepas intubasi dan setiap l 0 minit sebingga pembedahan 
selesai. Bispectral index scale (BIS) di pasang untuk menilai tahap pembiusan. 
Tahap stimulasi dalam menyedarkan pesakit terhad kepada sokongan secara lisan serta 
dengan menepuk babu secara perlaban setiap 10 saat. Masa dan perubahan nilai BIS dicatat 
bermula dari penutupan ubat bius sehingga pesakit membuka mata dan patuh kapada 
arafum yang ringkas. Semasa proses menyedarkan pesaldt, sebarang komplikasi 
diperhatikan dan dicatat. Komplikasi juga diperhatikan semasa dibilik pemulihan. 
Kajian ini mendapati terdapatnya perbezaan masa untuk mencapai tahap kesedaran selepas 
pembiusan diantara desflurane dan sevoflurane (7 .21±1.82 minit, tmtuk destlurane; 
12.55±2.70 minit, untuk sevotlurane: p<O.OOl) dan masa untuk mematuhi araban ringkas 
(8.33±1.77 minit, untuk destlurane; 13.52±2.65 minit, tmtuk sevoflurane: p<O.OOl) untuk 
pembedahan yang memakan masa Iebih kurang 2 jam. Perubahan pada. nilai BIS dengan 
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masa menunjukkan adanya perbezaan di mana ianya lebih cepat dengan destlurane 
berbanding dengan sevotlurane. Tetapi tiada perbezaan untuk tekanan darah dan denyutan 
nadi semasa pembiusan dijalankan diantara dua kumpulan. Terdapat 5 (16. 7%) kejadian 
komplikasi lDltuk kumpulan sevoflurane. Tetapi tiada perbezaan dari segi statistik. 
Ringkasan dari kajian ini menunjukkan destlurane mempunyai tahap kestabilan yang sama 
dengan sevotlurane dari segi tekanan darah dan denyutan nadi serta kesan samping tetapi 
desflurane mempunyai tahap kesedaran pembiusan yang cepat 
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ABSTRACT 
The safety of anaesthetic recovery is closely related to the speed of which the patient 
reaches a state of stable circulation, respiration and well maintained reflexes. Apart from 
the risk of surgical complications, the risk of residual anaesthetic effects, are the reason for 
keeping patients in a highly staffed, and high surveillance recovery unit. 
With the new rapidly eliminated inhalational anaesthetic agent, such as destlurane, having 
low blood gas solubility coefficient (0.42), it is supposed to offer a rapid recovery. The so-
called fast-track concept means that the patient is so well recovered when he leaves the 
operating theatre that tbe recovery unit may be by-passed without any risk for the patient. 
A randomized single blinded prospective study was conducted in Hospital Universiti Sains 
Malaysia from June 2004 to Jooe 2005 involving a total of 60 ASA I patients planned fur 
elective orthopedic procedures with duration of surgery less then 2 hours. The patients 
were allocated into 2 equally numbered groups, desflurane (n=30) and sevoflurane (n=30). 
The objectives of the study were to compare the effect of desflurane versus sevoflurane as 
inhalational agent for maintenance, on recovery time and side effects. 
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All patients were induced with intravenous fentanyl, propofol and atracurium. 
Intraoperatively, either desflurane 6% or sevoflurane 2% (which are equivalent to lMAC 
of both agents in 1000.4 oxygen) was used together with 30010 oxygen and 700,4, nitrous 
oxide. Atracmimn infusion was used as a muscle relaxant and fentanyl was given for 
analgesia. Hemodynamic parameters (blood pressure and heart rate) were recorded on 
arrival, pre ... intubation, post-intubation and every l 0 minutes until the end of the surgery. 
Bispectral index scale (BIS) was used to monitor anaesthetic depth. 
During emergence, stimulation of patients was limited to verbal encouragement to open 
eyes with a tap on the shoulder at 10 seconds interval. Time was recorded from 
discontinuation of anaesthetic until patients opened their eyes and obeyed simple 
commands. The changes in BIS values with time were recorded as the inhalational agent 
was discontinued. At the same time, patients were observed for any complications during 
emergence and at the recovery room. 
From this study, there was significant difference between desfturane and sevotlurane in 
tenns of recovery time, which included time to open eyes (7 .2l:r 1.82 minutes, for 
destlurane versus 12.55±2.70 minutes, for sevoflurane with p < 0.001) and time to obey 
command (8.33±1.77 minutes, for desflurane versus 13.52±2.65 for sevotlurane with p < 
0.001 ), with the duration of operation within 2 hours. The changes in BIS values with time 
showed significance difference between the groups, which was ~ with desflurane 
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groups. However, there was no significant difference in term of hemodynamic parameters 
between the groups. There were 5 (16. 7%) incidence of complications during 
emergence/recovery in patients who received sevoflurane. However it was not statistically 
significant. 
In summary, this study showed that desflurane has a faster recovery time with similar 
hemodynamic and side effects as compared to sevoflurane. 
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1. INTRODUCI'ION 
The history of ambulatory anaesthesia is as old as the history of anaesthesia itself. 
Expansion of outpatient anaesthesia proceeded slowly until the late 1970s and early 1980s. 
Webb and Graves, describing their experience from 1949 to 1959, estimated that an 
average of 1200 patients a year had outpatient surgery. This was S % of the total 
anaesthetics provided at their hospital. 
Further eXpansion of ambulatory anaesthesia was minimal until the mid-1980s. At that 
time, freestanding ~bulatory surgery centres began to proliferate,. as did hospital-based 
programs. By 1987, hospital-affiliated ambulatory surgery accounted for 9.8 million 
operations or about 45 % of the total surgery volmne in the United States (Henderson et 
al., 1991). 
The advantages of lower cost, lower rate of infection, less patient anxiety and greater 
convenience were well established (Poole et al., 1999). Factor involved is the development 
of new anaesthetics agents that allow patients to recover more rapidly. Furthermore, the 
development of technology gives us more advantages, for examples, to monitor patient,s 
depthness during anaesthesia by using Bispectrallndex Scale (BIS) which is invented in 
year 1996. 
BIS is a dimensionless number scaled from 0 - I 00, with I 00 represent as awake BEG and 
zero representiDg complete electrical silence (cortical suppression). Bispectrallndex Scale 
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(BIS) level between 45 and SS was targeted in. the BIS monitored patients where depth of 
anaesthesia ·was assessed by clinical criteria in the control group. Results showed 
Bispectral Index Scale monitoring reduced propofol usage and hastened recovery after 
propofol anaesthesia, whereas in desflurane anaesthesia it was associated with improved 
patient satisfaction (Luginbuhl et a/., 2003). Another study showed that the consumption of 
both propofol and sevoflurane decreased significantly (29% and 40%) with the use of 
Bispectrallndex Scale (Yii et al., 1999). 
The inhalational agents continue to have a prominent role in the provision of general 
anaesthesia. Among them, isoflurane is the commonest agent used in this country and also 
throughout the world. Many studies have been done on the ·use of isotlurane as an 
inbalationaJ agent. 
Now, with this new era of inhalational anaesthesia, these anaesthetic agents currently used, 
started being replaced by newer agents, which bave the characteristic features almost close 
to ideal anaesthetic properties. These include sevotlurane and destlurane (N.J.O Keeffe and 
T.EJ. Healy., 1999). Both provide a greater degree of control of anaesthetic depth and a 
more rapid immediate recovery from anaesthesia than is currently available with other 
inhaled agents because of their decreased solubility. 
Desflurane is currently used widely in the United States of America and parts of Europe. 
Compared with sevoflurane, desflurane has the additional advantage of being extremely 
resistant to degradation and biotransformation. 
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Sevotlurane is currently in widespread clinical use_ in )apan and parts of South America. 
Compared with desflurane, sevofturane has the additional advantage ofbeing non-irritating 
to the airway. Inhalational induction of anaesthesia with sevotlurane is achieved rapidly 
and easily. Meanwhile, desflurane is extmnely irritating to the airway when used as a 
inhalational induction agent (Young and Apfelbaum 1995). 
However, a study done by Mahmoud et al., (2001) and Eshima et al., (2003) found that 
there was no significant difference in respiratory responses between desfturane and 
sevoflurane given through the laryngeal mask airway (LMA). The instability of 
sevoflmane with carbon dioxide absorbents and its in vivo biotransformation, produce 
potentially toxic by-products particularly if used with low flow anaesthesia. However, a 
study done by Bito et a/.,(1997) on bmnan found that no significant difference in 
compound A production was observed during sevotlurane anaesthesia at a gas flow rate of 
2Umin versus 0.5 L/min. 
Having low blood gas solubility coefficient of 0.42, destlurane is supposed to offer rapid 
induction and recovery ftom its anaesthetic effects. Use of destlurane leads to a more rapid 
emergence and shorter time to extubation compared to sevotlurane (Nathanson et al., 
1995). 
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2. DEFINITIONS 
2.1 Sevotlurane; 
Fluorinated methyl isopropyl edter, use as anaesthetic inhalational agent. 
2.2 Desflurane; 
Fluorinated methyl ethyl ether, use as anaesthetic inhalational agent 
2.3 Recovery Time; 
Time from discontinuation of inhalational agents to opening eyes (eyes open) in response 
to call and to obey command (obey command) after completion of operation (recovery). 
2.4 Recovery Characteristic; 
Absence or presence of any complications during emergence from anaesthesia, and 
recovery period, such as breath holding, vomiting and laryngospasm. 
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3. OBJECI'IVES 
3.1 General Objective: 
To assess the advantages of desflurane as a new inhalational agent 
3.2 Specific Objectives: 
1. To determine whether desflurane has faster recovery time than sevotlurane. 
2. To determine that desflurane has less undesirable effect (vomiting, laryngospasm, 
and breath holding) during recovery time than sevofturane. 
3. To determine that desflurane is more haemodynamically stable than sevoflurane 
s 
4. LITERATURE REVIEWS 
4.1 Inhalational Anaesthetics history 
Inhalation anaesthetics are substances that are brought into the body via the hmgs and are 
distributed via the blood into the different tissues. The main target of inhalation 
anaesthetics is the brain. 
Inhaled anaesthetic agents include nitrous oxide (the oldest of all inhalational anaesthetics) 
and various halogenated agents: destlmane (halogenated solely with fluorine-halogenation 
increases potency and is essential to ensure non-flammability), halothane (halogenated 
with fluorine, cbJorine, and bromine), isoflurane (halogenated with fluorine and chlorine), 
and sevotlurane (halogenated solely with fluorine). 
Halothane was the first fluorinated inhalational anaesthetic that was wildly successful, 
rapidly displacing all other older potent inhaled anaesthetics. Efforts to develop other 
halogenated anaesthetics with more of the characteristics of the ideal inhaled anaesthetic 
agent than halothane led to the introduction of isoflurane, desflurane, and sevoflurane. 
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Figure 4.1 Possible mechanisms of action of inhalational anesthetics 
Inhaled anaesthetics act in different ways at the level of the central nervous system (Figure 
4. 1). They may disrupt normal synaptic transmission by interfering with the release of 
neurotransmitters from presynaptic nerve terminal (enhance or depress excitatory or 
inhibitory transmission), by altering the re-uptake of neurotransmitters, by changing the 
binding of neurotransmitters to the post-synaptic receptor sites, or by influencing the ionic 
conductance change that follows activation of the post-synaptic receptor by 
neurotransmitters. Both, pre- and postsynaptic effects have been found. 
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Direct interaction with the neuronal plasma membrane is very likely, but indirect action via 
productiOn of a second messenger also remains possible. The high correlation between 
lipid solubility and anaesthetic potency suggests that inhalation anaesthetics have a 
hydrophobic site of action. Inhalation agents may bind to both membrane lipids and 
proteins. It is at this time not clear which of the different theories are most likely to be the 
main mechanism of action of inhalation anaesthetics. 
The Meyer-Overton theory describes the correlation between lipid solubility of inhaled 
anaesthetics and MAC. It suggests that anaesthesia occms when a sufficient nwnber of 
inhalation anaesthetic molecules dissolve in the lipid cell membrane. The Meyer-Overton 
rule postulates that the nmnber of molecules dissolved in the lipid cell membrane and not 
the type of inhalation agent that causes anaesthesia. Combinations of different inhaled 
anaesthetics may have additive effects at the level of the ceU membrane. 
However, the Meyer-Overton theory does not describe why anaesthesia occurs. Critical 
Volume Hypothesis further expanded the Meyer-Overton rule. Critical Volume Hypothesis 
stated that the absorption of anaesthetic molecules could expand the volume of a 
hydrophobic region within the cell membrane and subsequendy distort channels necessary 
for sodium ion flux and development of action potentials necessary for synaptic 
transmission. The filet that anaesthesia occurs with significant increase in volume of 
hydrophobic solvents and is reversible by compressing the volume of the expanded 
hydrophobic region of the cell membrane supports Critical Volume Hypothesis. 
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The protein receptor hypothesis postulates that. protein receptors in the central nervous 
system are responsible for the mechanism of action of inhaled anesthetics. This theory is 
supported by the steep dose response curve for inhaled anesthetics. However, it remains 
tmclear if inhaled agents disrupt ion flow through membrane channels by an indirect action 
on the lipid membrane, via a second messenger, or by direct and specific binding to 
channel proteins. 
Another theory describes the activation of Gamma-Aminobutyric acid (GABA) receptors 
by the inhalation anesthetics. Volatile agents may activate GABA channels and 
hyperpolarize cell membranes. In addition, they may inhibit certain calcium channels and 
therefore prevent release of neurotransmitters and inhibit glutamate channels. Volatile 
anesthetics share common cellular actions with other sedative, hypnotic or analgesic drugs. 
Each of the above mentioned theories described a unitary theory of narcosis. They all 
concentrate more or less on unique site of action for inhaled anesthetics. The true 
mechanism of action of volatile anesthetics may be a combination of two or more such 
theories descnDed as multisite action hypothesis. Currently used inhalation anaesthetics 
include isotlurane, sevotlurane, destlurane and nitrous oxide. 
Ideally, inhalation agents should provide a quick induction and emergence from 
anaesthesia, good analgesia, muscle relaxation, easy maintenance of anaesthesia, rapid and 
predictable metabolism or elimination independent of renal and hepatic function, no 
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undesirable drug interactions, no side effects . or _toxicity. The intention is always to 
improve safety and to increase the control of the anaesthetic by the anaesthesiologist. 
History of inhalation anaesthetic started over 150 years ago (Figure 4.2). It began ·with the 
discovery of the anaesthetic properties of nitrous oxide, diethyl ether, and chlorofonn in 
the 1840s was followed by a hiatus of about 80 years before other inhaled anaesthetics 
were introduced. Then these were followed by ethylene, cyclopropane, trichloroethylene, 
isopropenyl vinyl in the 1930's and 1940's. In 1950, all inhaled anaesthetics, with the 
exception of nitrous oxide, were flammable or potentially toxic to the fiver. 
Halothane, a halogenated hydrocarbon was synthesized in 1951 and subsequently 
introduced into clinical practice in 1956. Shortly thereafter methoxyflurane appeared in the 
early 60's followed by entlurane and isoflurane in the 70's. Methoxyflurane was pulled 
from the market because of its nephrotoxic potential. Two other inhalation anaesthetics 
were synthesized in the 70's but were only introduced early 90's. The first of the two, 
sevoflurane was introduced in 1990 in Japan although it was first invented in United 
States. Desflurane was introduced into clinical practice in 1992. 
Currently, both sevoflurane and desflurane have gained approval and acceptance for use in 
Great Britain, United States and most of other countries. However, desfturane is still new 
in Malaysia, and it is still not widely used. 
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Figure 4.2 Inhaled anaesthetics introduced into clinical practice. 
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4.2 Physical Properties ofDesflurane 
Desflurane is a fluorinated methyl ethyl ether (Figure 4.3) differing from isoflurane only in 
the substitution of fluorine for chlorine on the alpha-ethyl carbon (Figure 4.4). 
Figure 4.3 Chemical structures of desflurane. 
Figure 4.4 Chemical structures of isoflurane. 
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Desflurane has a pungent odor (figure 4.5). The boiling point of desflurane is 22.8C and it 
saturated vapor pressure is 664 mmHg at 20 C. So, desflurane would boil at normal 
operating room temperature. Therefore, it cannot be administered with a standard 
vaporizer. A new type of vaporizer technology addresses this property, producing a 
regulated concentration by converting desflurane to a gas (heated and pressurized 
vaporizer that requires electrical power), which is then blended with diluent fresh gas flow 
(Figure 4.6). 
Figure 4.5 Inhalational agent, desflurane 
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Figure 4.6 TEC 6 vaporizer 
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The ideal anaesthetic agent produces anaesthesia while allowing the use of a high 
concetttration of oxygen. The minimmn alveolar concentration (MAC) of an anaesthetic 
agent at one atmosphere that abolishes movement in response to a noxious stimulus in 50010 
of subjects provides the standard definition of inhaled anaesthetic potency. In 30 to 60 
year-old patients, MAC values for desflurane is 6.0% at one a1mosphere, which indicates 
the potency and can be given with a high concentration of oxygen. By contrast, the MAC 
for nitrous oxide is 104% at one atmosphere, and it must be given in a pressurized chamber 
due to safety considerations. 
Solubility of an anaesthetic agent in blood is quantified as the blood:gas partition 
coefficient, which is the ratio of the concen1ration of an anaesthetic in the blood phase to 
the concentration of the anaesthetic in the gas phase, when the anaesthetic is in equilibrium 
between the two phases. 
A low blood:gas partition coefficient reflects a low affinity of blood for the anaesthetic, a 
desirable property because it predicts a more precise control over the anaesthetic state and 
a more rapid recovery from anaesthesia. The blood:gas partition coefficients for inhaled 
anaesthetics vary fiom a low of about 0.4S for nitrous oxide and desfturane and 0.6S for 
sevotlurane to 1.4 for isoflurane and 2.4 for halothane. 
Destlurane has a blood:gas partition coefficient of 0.42 (Eger, 1987), the lowest of all of 
the available volatile agents which means equilibration and recovery are likely to occur 
quickly. 
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4.3 Clinical Properties ofDestlurane 
4.3.1 Induction of anaesthesia 
Destlurane has a blood:gas partition coefficient of 0.42 (Eger, 1987), the lowest of all of 
the available volatile agents wbich means equilibration are likely to occur quickly and 
leads to rapid induction and rapid recovery. However, the ability to deliver an inspired 
concentration sufficiendy high to induce anaesthesia is limited by the effects of the 
anaesthetic vapor on the patient's airway. 
As we know that destlurane has a pungent odor. This made desflurane extremely irritating 
to the airway and, therefore, is not really suitable for induction of anaesthesia. The 
initability grading was destlurane > isotlurane > sevotlurane (TerRiet et al., 2000). They 
compared the pungency and tolerability of the inhaled anaesthetics in eighty-one 
unpremedicated patients (n=27, each group) inhaled 2 MAC of isoflurane (2.3%), 
desflurane {12%) or sevoflurane (4%) for 60 seconds ftom an anaesthetic breathing circuit 
via a mask. They found that one sevoflurane patient coughed, but completed the study 
period, whereas II isoflurane patients and 20 desfturane patients coughed, objected 
verbally or removed the mask forcefully. 
Both desflurane and isoflurane are pungent, Wilhelm et al. (1998) studied destlurane in 
comparison with isofturane on the effects of intubation fm tenn of heart rate and blood 
pressure) in paediatric ENT patients and they found that intubation conditions were better 
for desflurane (excellent or good 20 of22) than for isoflurane (12 of20). 
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Van Hemelrijck et al. (1991) studied desflurane in comparison with propofol-nitrous oxide 
in outpatients W1dergoing laparoscopic procedures. They fotmd that inhalation inductions 
were associated with high incidence of apnoea (26%), breath holding (390A.), and coughing 
(22%) in desflurane alone group. However the above incidence reduced with desflurane-
nitrous oxide group. 
Smooth induction of anaesthesia is best carried out using either an intravenous induction 
agents or sevofturane and when the patient is anaesthetized then only destlurane gradually 
introduced for maintenance anaesthesia. 
4.3.2 Maintenance of Anaesthesia. 
The important of maintenance anaesthesia is to achieve an appropriate "depth" of 
anaesthesia. These are done by titrating the inhalational anaesthetic agents given to the 
patients. It is important to recognize that equilibration between the two phases means the 
same partial pressure exists in both phases. Equilibration does not mean equality of 
concentration in two bio-pbases. 
Factors determining partial pressure gradients for establishment of anaesthesia are (a) 
transfer of inhaled. anaesthetic from anesthetic machine to alveoli (anaesthetic input) which 
in turn depends on inspired partial pressure, alveolar ventilation, characteristics of 
anaesthetic breathing system, and fimctional residual capacity of individual patient, (b) 
transfer of inhaled anaesthetic from alveoli to arterial blood (anaesthetic loss) which in tum 
depends on blood:gas partition coefficient, cardiac output, and alveolar to venous partial 
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pressure difference, and (c) transfer of inhaled anaesthetic from arterial blood to brain 
(anaesthetic loss) which in turn depends on brain: blood partition coefficient, cerebral blood 
flow, and arterial to venous partial pressure difference (Figure 4.7). 
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Figure 4.7 Anaesthetic circuits 
Because desflurane has low blood and tissue solubility, it would be expected that 
equilibration between the inspired concentration and the blood concentration should occur 
more rapidly and to a greater degree than with other volatile agents. This gives more 
control over depth of anaesthesia, and should mean more rapid recovery. 
There was faster equilibration between inhaled and exhaled concentrations of desflurane 
compared with isoflurane (Lee et a!., 1993). The alveolar concentration closely 
approximates the blood concentration. After 5 minutes, the ratio of alveolar and inhaled 
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concentration for desflurane was 0.9, whereas after 1 hour, the ratio of alveolar and inhaled 
concentration for isotlurane was still 0. 15. 
There have been several studies that examined the use of desflurane in patients undergoing 
cardiac surgery. Thomson et al. (1991) compared the use ofdesfturane with isotlurane in 
patients undergoing coronary artery surgery. They found no difference in the incidence of 
elec1rocardiograpbic changes, indicating myocardial ischaemia, or in outcome. Desflurane 
does not sensitize the myocardium to epinephrine (Moore et al., 1993), although desflurane 
can slow atrioventricular conduction (Bohan et al., 1992) and can cause junctional 
bradycardia (Rampil et al., 1989). 
Parsons et al. (1994) compared anaesthesia with destlurane and low-dose fentanyl with 
high-dose fentanyl and midazolam in patients undergoing coronary artery bypass surgery. 
They found that destlurane group had lower heart rates and blood pressures throughout the 
procedures. Again there was no measurable difference in outcome between the two groups. 
At concentration up to 1.0 MAC~ neither sevoftumne nor destlurane increased heart rate, 
whereas isoflurane caused an initial increase in heart rate that was sustained with 
increasing MAC (Ebert TJ et al., 1995). However, in the study, they also found that at 
above 1.0 MAC, both desflurane and sevoflurane were associated with an increase in heart 
rate, and the increase was more pronounced with destlurane. Rapid increases in inspired 
concentrations of either isoflurane or desfturane have been shown to initiate tachycardia 
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(Bedforth et al., 2000). The use of nitrous oxide with desflurane may diminish this effect 
(Cahalan et al., 1991 ). 
Mean arterial blood pressure was measured in adult volunteers who were not 
premedicated. Sevoflurane, isotlurane, and desflunme produced dose-dependent decreases 
in mean arterial blood pressure, and the effects were comparable (Ebert TJ et al., 1995). 
Desflurane cause the cardiac index to remain tmcbanged, while the systemic blood 
pressure falls in ventilated patients. In spontaneously breathing patients, the cardiac index 
increased (Weiskopf et al., 1991). 
Destlurane cause peripheral vasodilatation (Jones et al., 1990), direct coronary 
vasodilation (Merin et al., 199 I) and produced an overall reduction in cardiac work (Boban 
et al., 1992). A progressive decreased in forearm vascular resistance was observed with 
increasing concentrations of sevotlurane, isoflurane, and desflurane (Ebert et al., I 995). 
This decrease became statistically significantly lower with sevotlurane at 1.5 MAC than 
with desflurane or isoflurane. These makes potential improvement in coronary blood flow 
was offset by a filii in the perfusion pressure resulting ftom the peripheral vasodilatation 
and dte tachycardia. It also rises the potential for coronary steal syndrome. However, 
Hartman et al., (1991) failed to find any evidence for this, using a canine model of 
coronary artery disease. 
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Other pharmacodynamic effects of desflurane .on various organ systems are similar with 
other inhalational anaesthetics. Desflurane produced a dose-dependent decrease in tidal 
volume with an increase in respiratory rate (Lockhart et al., 1991). The net effect was a 
reduction in minute alveolar ventilation (Jones et al., 1990). There was an increase in 
arterial carbon dioxide levels and a depression of the ventilatory response to carbon 
dioxide. There was also an increase in the in1rapubnonary shunt ftaction and an increase in 
the physiological dead space (Lockhart et al., 1991). 
At concentrations of 6% destlurane is extremely initating to the airway. It caused 
coughing, breath holding, and laryngospasm, making it lDlsuitable for use for inhalation 
induction in both children and adult (Zwass et al., 1992; Bunting et al., 1995). The 
mechanism is unknown but it was believed that there are sites in the upper airway (larynx 
and above) that respond with sympathetic activation during rapid increases in destlurane 
concentration independent of systemic anaesthetic changes. These responses, while lesser 
than those seen with rapid increases to the lung may represent direct irritation of airway 
mucosa. Eshima et al., (2002), showed that there was no significant difference in airway 
responses during desflurane and sevotlurane administration via a laryngeal mask airway 
for maintenance of anaesthesia. 
Eger et al., (1994), found that there was no evidence of bronchospasm during induction of 
anaesthesia in asthmatics with destlurane and in vitro studies. This suggests that desflurane 
produces concentration-dependent bronchodilation as with other inhalational agents 
(Mazzeo et al., 1 994; Park et al., 1998). 
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Destlurane significantly depressed neuromuscular function, reducing the force of 
contraction of the adductor poUicis muscle and increasing the degree of titanic fade 
(Caldwell et al., 1991 ). It also provided sufficient relaxation to allow tracheal intubation. 
Destlurane potentiated the action of muscle relaxants similar to the other volatile agents 
(Caldwell et al., 1991; Lee et al., 1992; Ghouri & White., 1991). The above effects were 
more pronounce with destlurane than propofol (Zhou TJ et al., 2000). Routine monitoring 
of neuromuscular activity is recommended even when a single bolus dose of muscle 
relaxant is administered during anaesthesia. 
Rampil et al., (1988) showed that destlurane had an effect on the EEG similar to 
isofturane, producing burst supptession at lower doses. At an MAC greater than 1.66%, the 
EEG becomes isoelectric. In human volunteers, it produced burst suppression at 
concentration above 1.24 MAC (RampiJ et a1., l99la), with no evidence of epileptifonn 
activity, despite attempts to provoke excitatory activity experimentally. There have been 
no reports of epileptiform activity associated with desflurane to date. 
Lutz et al., (1990) demonstrated in dogs that destlurane produces dose-dependent cerebral 
vasodilation. It also produced a dose-dependent reduction in cerebral metabolism 
(Newberg et al., 1983). Strebel et al., (1995) showed that autoregulation was impaired 
1D1der desflurane anaesthesia, when compared with propofbl .. Ornstein et al., (1993) 
demonstrated that in humans with intracranial mass lesions, the effect of desflurane on the 
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cerebral circulation was similar to isotlurane · and- that the cerebrovascular response to 
carbon dioxide was maintained. 
Talke et al., (1996) compared the effect of destlurane and isoflurane on lumbar CSF 
pressure in normocapnic patients without an intracranial mass lesion anaestheti~ with 
propofol infusion. They found that both destlurane and isotlurane at 0.5 and 1 MAC, 
respectively, were associated with an increase in CSF pressure under these conditions. 
Despite advances in anaesthetic technique and technology, intraoperative awareness 
continues to occur with alarming regularity. The psychological effects on patients and the 
medicolegal consequences to providers have created the need for a reliable monitor of the 
hypnotic component of anaesthesia. 
A new technology known as bispectral index scales (BIS) has the potential to put an end to 
the devastating occurrence of intraoperative awareness, as well as improve the overall 
effectiveness of anaesthetic delivery and surgical experience (Ouellette et al., 1998). 
Bispectral index scale measures the hypnotic effect of anaesthetic and sedative agents on 
the brain and records a single number that ranges fiom zero (absence of brain activity) to 
100 (completely awake). The BIS monitor provides a continuous measurement of the 
hypnotic state or state of consciousness, awareness, and recall. 
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A BIS sensor is required for obtaining the brain activity signal from a patient. The sensor 
can either be a one-piece sensory strip, which has location markers to facilitate placement, 
or four individual leads placed on the patient at specific sites (Figure 4.8). 
Figure 4.8 Bispectral Index Scale sensor placed on the patient. 
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